Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastoma

PURPOSE: Malignant glioma (MG) is the most deadly primary brain cancer. Signaling though the PI3K/AKT/mTOR axis is activated in most MGs and therefore a potential therapeutic target. The mTOR inhibitor temsirolimus and the AKT inhibitor perifosine are each well‐tolerated as single agents but with li...

Full description

Saved in:
Bibliographic Details
Published in:Ann Clin Transl Neurol
Main Authors: Kaley, Thomas J., Panageas, Katherine S., Pentsova, Elena I., Mellinghoff, Ingo K., Nolan, Craig, Gavrilovic, Igor, DeAngelis, Lisa M., Abrey, Lauren E., Holland, Eric C., Omuro, Antonio, Lacouture, Mario E., Ludwig, Emmy, Lassman, Andrew B.
Format: Artigo
Language:Inglês
Published: John Wiley and Sons Inc. 2020
Subjects:
Research Articles
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7187704/
https://ncbi.nlm.nih.gov/pubmed/32293798
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/acn3.51009
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items